51 related articles for article (PubMed ID: 20805306)
1. Pharmacological properties of revefenacin (TD-4208), a novel, nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues.
Hegde SS; Pulido-Rios MT; Luttmann MA; Foley JJ; Hunsberger GE; Steinfeld T; Lee T; Ji Y; Mammen MM; Jasper JR
Pharmacol Res Perspect; 2018 Jun; 6(3):e00400. PubMed ID: 29736245
[TBL] [Abstract][Full Text] [Related]
2. Changes in Membrane Cholesterol Differentially Influence Preferential and Non-preferential Signaling of the M1 and M3 Muscarinic Acetylcholine Receptors.
Michal P; El-Fakahany EE; Doležal V
Neurochem Res; 2015 Oct; 40(10):2068-77. PubMed ID: 24821386
[TBL] [Abstract][Full Text] [Related]
3. Novel long-acting antagonists of muscarinic ACh receptors.
Randáková A; Rudajev V; Doležal V; Boulos J; Jakubík J
Br J Pharmacol; 2018 May; 175(10):1731-1743. PubMed ID: 29498041
[TBL] [Abstract][Full Text] [Related]
4. Mutagenesis of nucleophilic residues near the orthosteric binding pocket of M1 and M2 muscarinic receptors: effect on the binding of nitrogen mustard analogs of acetylcholine and McN-A-343.
Suga H; Sawyer GW; Ehlert FJ
Mol Pharmacol; 2010 Oct; 78(4):745-55. PubMed ID: 20643905
[TBL] [Abstract][Full Text] [Related]
5. Functional M3 muscarinic acetylcholine receptors in mammalian hearts.
Wang Z; Shi H; Wang H
Br J Pharmacol; 2004 Jun; 142(3):395-408. PubMed ID: 15148264
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the activation kinetics of the M3 acetylcholine receptor and a constitutively active mutant receptor in living cells.
Hoffmann C; Nuber S; Zabel U; Ziegler N; Winkler C; Hein P; Berlot CH; Bünemann M; Lohse MJ
Mol Pharmacol; 2012 Aug; 82(2):236-45. PubMed ID: 22564786
[TBL] [Abstract][Full Text] [Related]
7. In vitro anticholinergic drugs affect CD8+ peripheral blood T-cells apoptosis in COPD.
Profita M; Riccobono L; Montalbano AM; Bonanno A; Ferraro M; Albano GD; Gerbino S; Casarosa P; Pieper MP; Gjomarkaj M
Immunobiology; 2012 Mar; 217(3):345-53. PubMed ID: 21855166
[TBL] [Abstract][Full Text] [Related]
8. Chemical lead optimization of a pan G(q) mAChR M(1), M(3), M(5) positive allosteric modulator (PAM) lead. Part I: Development of the first highly selective M(5) PAM.
Bridges TM; Kennedy JP; Cho HP; Breininger ML; Gentry PR; Hopkins CR; Conn PJ; Lindsley CW
Bioorg Med Chem Lett; 2010 Jan; 20(2):558-62. PubMed ID: 20004578
[TBL] [Abstract][Full Text] [Related]
9. Muscarinic receptors promote pacemaker fate at the expense of secondary conduction system tissue in zebrafish.
Burczyk MS; Burkhalter MD; Tena TC; Grisanti LA; Kauk M; Matysik S; Donow C; Kustermann M; Rothe M; Cui Y; Raad F; Laue S; Moretti A; Zimmermann WH; Wess J; Kühl M; Hoffmann C; Tilley DG; Philipp M
JCI Insight; 2019 Oct; 4(20):. PubMed ID: 31619590
[TBL] [Abstract][Full Text] [Related]
10. Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease.
Ora J; Coppola A; Cazzola M; Calzetta L; Rogliani P
J Exp Pharmacol; 2020; 12():559-574. PubMed ID: 33324119
[TBL] [Abstract][Full Text] [Related]
11. LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review.
Rogliani P; Calzetta L; Braido F; Cazzola M; Clini E; Pelaia G; Rossi A; Scichilone N; Di Marco F
Int J Chron Obstruct Pulmon Dis; 2018; 13():3115-3130. PubMed ID: 30323582
[TBL] [Abstract][Full Text] [Related]
12. Umeclidinium in chronic obstructive pulmonary disease: latest evidence and place in therapy.
Babu KS; Morjaria JB
Ther Adv Chronic Dis; 2017 Apr; 8(4-5):81-91. PubMed ID: 28491268
[TBL] [Abstract][Full Text] [Related]
13. Ozone-Induced Hypertussive Responses in Rabbits and Guinea Pigs.
Clay E; Patacchini R; Trevisani M; Preti D; Branà MP; Spina D; Page C
J Pharmacol Exp Ther; 2016 Apr; 357(1):73-83. PubMed ID: 26837703
[TBL] [Abstract][Full Text] [Related]
14. Muscarinic receptors and their antagonists in COPD: anti-inflammatory and antiremodeling effects.
Karakiulakis G; Roth M
Mediators Inflamm; 2012; 2012():409580. PubMed ID: 23226927
[TBL] [Abstract][Full Text] [Related]
15. Bronchodilator activity of (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino] carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407), a potent, long-acting, and selective muscarinic M3 receptor antagonist.
Villetti G; Pastore F; Bergamaschi M; Bassani F; Bolzoni PT; Battipaglia L; Amari G; Rizzi A; Delcanale M; Volta R; Cenacchi V; Cacciani F; Zaniboni M; Berti F; Rossoni G; Harrison S; Petrillo P; Santoro E; Scudellaro R; Mannini F; Geppetti PA; Razzetti R; Patacchini R; Civelli M
J Pharmacol Exp Ther; 2010 Dec; 335(3):622-35. PubMed ID: 20805306
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases.
Salmon M; Luttmann MA; Foley JJ; Buckley PT; Schmidt DB; Burman M; Webb EF; DeHaas CJ; Kotzer CJ; Barrett VJ; Slack RJ; Sarau HM; Palovich MR; Lainé DI; Hay DW; Rumsey WL
J Pharmacol Exp Ther; 2013 May; 345(2):260-70. PubMed ID: 23435542
[TBL] [Abstract][Full Text] [Related]
17. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile.
Gavaldà A; Miralpeix M; Ramos I; Otal R; Carreño C; Viñals M; Doménech T; Carcasona C; Reyes B; Vilella D; Gras J; Cortijo J; Morcillo E; Llenas J; Ryder H; Beleta J
J Pharmacol Exp Ther; 2009 Nov; 331(2):740-51. PubMed ID: 19710368
[TBL] [Abstract][Full Text] [Related]
18. The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide.
Gavaldà A; Ramos I; Carcasona C; Calama E; Otal R; Montero JL; Sentellas S; Aparici M; Vilella D; Alberti J; Beleta J; Miralpeix M
Pulm Pharmacol Ther; 2014 Aug; 28(2):114-21. PubMed ID: 24928173
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
